Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) Shares Outstanding (Weighted Average) (2023 - 2026)

Prelude Therapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $82.5 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 8.6% to $82.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $82.5 million, a 8.6% increase, with the full-year FY2025 number at $19.5 million, down 74.23% from a year prior.
  • Shares Outstanding (Weighted Average) hit $82.5 million in Q1 2026 for Prelude Therapeutics, up from $19.5 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for PRLD hit a ceiling of $82.5 million in Q1 2026 and a floor of $19.5 million in Q4 2025.
  • Historically, Shares Outstanding (Weighted Average) has averaged $69.4 million across 4 years, with a median of $75.8 million in 2024.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): rose 25.6% in 2024 and later plummeted 74.23% in 2025.
  • Tracing PRLD's Shares Outstanding (Weighted Average) over 4 years: stood at $60.4 million in 2023, then rose by 25.6% to $75.8 million in 2024, then plummeted by 74.23% to $19.5 million in 2025, then soared by 322.48% to $82.5 million in 2026.
  • Business Quant data shows Shares Outstanding (Weighted Average) for PRLD at $82.5 million in Q1 2026, $19.5 million in Q4 2025, and $76.0 million in Q3 2025.